Radiotherapy plays a central part in curing cancer. For decades, most research on
improving treatment outcomes has focused on modulating radiation-induced biological …

The phosphoinositide 3-kinase (PI3K) pathway plays an integral role in many cellular
processes and is frequently altered in cancer, contributing to tumor growth and survival …

The mammalian target of rapamycin (mTOR) is a crucial signaling node that integrates
environmental cues to regulate cell survival, proliferation and metabolism, and is often …

Approximately 50% of all patients with cancer receive radiation therapy at some point during
the course of their treatment, and the majority of these patients are treated with curative …

Abstract The phosphoinositide 3-kinase (PI3K) pathway is an intracellular signaling pathway
that has regulatory roles in cell survival, proliferation, and differentiation, and a critical role in …

Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic
ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application. Here we test …

The PI3K pathway is hyperactivated in most cancers, yet the capacity of PI3K inhibitors to
induce tumor cell death is limited. The efficacy of PI3K inhibition can also derive from …

The PI3K–AKT–mTOR pathway is frequently activated in cancer. PI3K inhibitors, including
the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-selective inhibitor alpelisib …

Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation in squamous
cell carcinoma of the head and neck contributes to treatment resistance and disease …

Pancreatic ductal adenocarcinoma (PDAC) is considered a non‐immunogenic tumor, and
immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT) …